Abstract
Amoebiasis, a disease caused by Entamoeba histolytica, remains a major health problem that afflicts several million people worldwide. Moreover, in recent years there has been a rise in the number of reports with amebic brain abscess as well as in developed countries the microorganisms that cause diarrheal diseases are a cause of concern because of their potential to be used as bioterrorist agent. Metronidazole, an antiamoebic agent, is the drug of choice for treating amoebiasis in humans, but it has been shown to be both mutagenic and carcinogenic in bacteria and rodents respectively. The completely safe treatment for this disease does not exist at present and therefore newer and safer agents are required either from synthetic or natural resources. This review covers brief description of the disease, plant secondary metabolites and synthetic compounds that have exhibited moderate to high activity in vitro and in vivo bioassays against E. histolytica. The review also discusses some of the key biochemical targets that are unique and vital for the existence and growth of the parasite which are being further exploited so as to search for therapeutically active antiamoebic agents.
Keywords: Entamoeba histolytica, paromomycin, antiamoebic activity, antiplasmodial, Carbamic acid, Alkylphosphocholines
Current Bioactive Compounds
Title: Targeting Amoebiasis: Status and Developments
Volume: 3 Issue: 2
Author(s): A. Azam and S. M. Agarwal
Affiliation:
Keywords: Entamoeba histolytica, paromomycin, antiamoebic activity, antiplasmodial, Carbamic acid, Alkylphosphocholines
Abstract: Amoebiasis, a disease caused by Entamoeba histolytica, remains a major health problem that afflicts several million people worldwide. Moreover, in recent years there has been a rise in the number of reports with amebic brain abscess as well as in developed countries the microorganisms that cause diarrheal diseases are a cause of concern because of their potential to be used as bioterrorist agent. Metronidazole, an antiamoebic agent, is the drug of choice for treating amoebiasis in humans, but it has been shown to be both mutagenic and carcinogenic in bacteria and rodents respectively. The completely safe treatment for this disease does not exist at present and therefore newer and safer agents are required either from synthetic or natural resources. This review covers brief description of the disease, plant secondary metabolites and synthetic compounds that have exhibited moderate to high activity in vitro and in vivo bioassays against E. histolytica. The review also discusses some of the key biochemical targets that are unique and vital for the existence and growth of the parasite which are being further exploited so as to search for therapeutically active antiamoebic agents.
Export Options
About this article
Cite this article as:
Azam A. and Agarwal M. S., Targeting Amoebiasis: Status and Developments, Current Bioactive Compounds 2007; 3 (2) . https://dx.doi.org/10.2174/157340707780809590
DOI https://dx.doi.org/10.2174/157340707780809590 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bacteriophages and Phage-Derived Proteins – Application Approaches
Current Medicinal Chemistry Concomitant Gene Mutations of MBL and CYBB in Chronic Granulomatous Disease: Implications for Host Defense
Inflammation & Allergy - Drug Targets (Discontinued) Synthetic Cathinones: A New Public Health Problem
Current Neuropharmacology Application of Radioisotopes in Inflammation
Current Medicinal Chemistry Immune Therapy of Multiple Sclerosis - Future Strategies
Current Pharmaceutical Design Pharmacodynamics and Pharmacokinetics of Antifungals for Treatment of Invasive Aspergillosis
Current Pharmaceutical Design Targeting Inflammatory Bowel Diseases by Nanocarriers Loaded with Small and Biopharmaceutical Anti-Inflammatory Drugs
Current Pharmaceutical Design Role of β7 Integrins in Intestinal Lymphocyte Homing and Retention
Current Molecular Medicine Radionuclide Imaging in Drug Development
Current Pharmaceutical Design Application of NMR Spectroscopy in Medicinal Chemistry and Drug Discovery
Current Topics in Medicinal Chemistry Nanoparticulate Iron Oxide Contrast Agents for Untargeted and Targeted Cardiovascular Magnetic Resonance Imaging
Current Nanoscience Proliferation Markers for the Differential Diagnosis of Tumor and Inflammation
Current Pharmaceutical Design Acute Cardioembolic Cerebral Infarction: Answers to Clinical Questions
Current Cardiology Reviews Anti-Inflammatory and Anti-Allergy Drugs in Rhinosinusitis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Medical Complications in Anorexia and Bulimia Nervosa
Endocrine, Metabolic & Immune Disorders - Drug Targets Does It Make Sense that Diabetes is Reciprocally Associated with Periodontal Disease?
Endocrine, Metabolic & Immune Disorders - Drug Targets Flavonoids: A Review of Its Commercial Application Potential as Anti- Infective Agents
Current Medicinal Chemistry - Anti-Infective Agents CT-negative Subarachnoid Hemorrhage Caused by Telangiectasia: A Case Report
Current Medical Imaging Tuberculosis Infections of the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Hydatid Disease: Current Status of Chemotherapy and Drug Delivery Systems
Current Drug Therapy